İbrahim Saraç

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Papers of special note have been highlighted as: • of interest; • • of considerable interest • None Platelet-to-hemoglobin ratio as a novel predictor of long-term adverse outcomes in patients after percutaneous coronary intervention: a retrospective cohort study . 27(19), 2216–2219 ( ). • • The platelet-to-hemoglobin ratio is a marker of adverse cardiovascular effects. 27(19), 2216–2219 (). • • The platelet-to-hemoglobin ratio is a marker of adverse cardiovascular effects.

1. Introduction The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), affected millions and killed hundreds of thousands of people [1]. As a result of the measures taken against the spread of the disease or reducing the effectiveness of the pathogen in the body, the severity of the disease has decreased relatively. However, COVID-19 still exists with different mutants [2].